| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.0087 | 0.9 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | tubastatin A | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.9 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | simvastatin | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |